Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25574445 | 0.84 | ALDH1A1 (0.42) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL2611076 | 0.79 | ALDH1A1 (0.47) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL19283903 | 0.76 | LMNA (0.47) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL19283998 | 0.76 | ALDH1A1 (0.44) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL16668566 | 0.74 | L3MBTL1 (0.38) | ALDH1A1SMN1; SMN2MAPTCCR1CCR5 | |
| SCHEMBL12045706 | 0.74 | ALDH1A1 (0.42) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL22807296 | 0.73 | CCR1 (0.42) | KDM4EKMT2AALDH1A1SMN1; SMN2CCR1 | |
| SCHEMBL1424278 | 0.73 | ALDH1A1 (0.48) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL30441269 | 0.73 | ALDH1A1 (0.48) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL4741484 | 0.72 | CYP1A2 (0.47) | LMNAKDM4EKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003400-B | 2-Formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024083086-A1 | BICYCLIC DERIVATIVE INTEGRIN INHIBITOR | 上海如凌生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117903171-A | Integrin inhibitors of a class of bicyclic derivatives | 上海如凌生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114100588-B | Nitrogen-containing functional group ultrahigh crosslinked adsorbent, preparation method thereof and blood perfusion device | 泉州师范学院 | 2024-03-22 | — | — | CN | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-116003400-A | 2-formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2023-04-25 | — | — | CN | disclosed |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-21 | — | — | US | disclosed |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | TERNS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-113234072-B | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1196384-A4 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1196384-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6211184-B1 | TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5981546-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | LMNA 4571/4885KDM4E 1217/4885KMT2A 2300/4885 |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | LMNA 3637/4885KDM4E 1768/4885KMT2A 3589/4885 |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | LMNA 4675/4885KDM4E 583/4885KMT2A 1907/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | LMNA 3788/4885KDM4E 2532/4885KMT2A 4230/4885 |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | FGFR4, FGFR1, FGFR3 | LMNA 3880/4885KDM4E 250/4885KMT2A 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.